PMVP (PMV Pharmaceuticals) Stock Based Compensation: $5.81 Mil (TTM As of Mar. 2026)


PMVP PMV Pharmaceuticals Inc PMVP
34 GF Score
Price $1.26
! 2 Warning Signs
View Full Analysis

What is PMV Pharmaceuticals Stock Based Compensation?

PMV Pharmaceuticals PMVP +1.21% 34 Stock Based Compensation is $5.81 Mil as of Mar. 2026. GuruFocus rates PMVP with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

PMV Pharmaceuticals's Stock Based Compensation for the three months ended in Mar. 2026 was $1.39 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $5.81 Mil.

PMV Pharmaceuticals Stock Based Compensation Related Terms

PMV Pharmaceuticals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for PMV Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PMV Pharmaceuticals Stock Based Compensation Chart

PMV Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 5.34 10.20 12.38 8.87 5.92

PMV Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.51 1.67 1.38 1.37 1.39
PMVP
34GF Score
PMV Pharmaceuticals Inc PMVP
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PMV Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.81 Mil.

What does a Stock Based Compensation of $5.81 Mil mean?
PMV Pharmaceuticals (PMVP) has a Stock Based Compensation of $5.81 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for PMV Pharmaceuticals and its competitors.
Is PMV Pharmaceuticals' Stock Based Compensation too high?
PMV Pharmaceuticals' current Stock Based Compensation is $5.81 Mil. Overall, PMV Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does PMV Pharmaceuticals' Stock Based Compensation compare to MNOV and TCRX?
PMV Pharmaceuticals' Stock Based Compensation of $5.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for PMV Pharmaceuticals and its competitors. PMV Pharmaceuticals's current Stock Based Compensation is $5.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PMV Pharmaceuticals stock overvalued right now?
PMV Pharmaceuticals (PMVP) has a current Stock Based Compensation of $5.81 Mil. The current Stock Based Compensation is $5.81 Mil. PMV Pharmaceuticals' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For PMV Pharmaceuticals (PMVP), the current Stock Based Compensation is $5.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PMV Pharmaceuticals Business Description

Address 400 Alexander Park Drive, Suite 301, Princeton, NJ, USA, 08540
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
34GF Score

Get the complete analysis for PMVP

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price